Abstract
The detection and quantification of protoporphyrin IX (PpIX) is an important diagnostic tool in various medical fields, including dermatology and oncology.1 – 3 Within dermatology, PpIX-based skin photodynamic therapy (PDT) is increasingly used for the clinical treatment of actinic keratosis (AK) lesions, replacing traditional cryosurgery, chemical peel, and curettage treatments.4,5 Despite the widespread clinical use of skin PDT, the primary treatment outcome of AK lesion clearance rates varies widely, which is primarily caused by heterogeneous accumulation of the photosensitizer PpIX between patients and between lesions.6,7 Furthermore, the presence and accumulation of PpIX in skin is also related to conditions like porphyria8,9 and can be used for the preoperative mapping of non-melanoma skin cancers.10,11 Therefore, the ability to visualize and quantify skin PpIX in clinical settings can be used to help guide critical decisions at the point-of-care, including mitigative actions to improve patient outcomes. Imaging and spectroscopy techniques have shown potential for PpIX quantification, with fluorescence (FL) imaging techniques demonstrating great promise for non-invasive measurement of PpIX in the skin.6,12 Additionally, smartphone-based imaging (SBI) devices have emerged as a promising approach for PpIX quantification, offering cost-effective solutions that could be integrated into the clinical workflow.13 – 15

This publication has 37 references indexed in Scilit: